Netherlands-based venture capital firm BioGeneration Ventures (BGV) closed its third fund at €82m ($95.5m) today, having secured capital from limited partners including pharmaceutical firms Bristol-Myers Squibb and Johnson & Johnson (J&J).
The fund’s LPs also include European Investment Fund (EIF), private equity firm Schroder Adveq, and Man Pension Trust, which manages the pension funds of mechanical engineering firm Man’s employees. J&J invested through its Johnson & Johnson Innovation – JJDC unit.
BGV III seeks to identify early-stage opportunities in the…
